Diabetes Prevention Program

Obesity Research Center

For more information on this program, please visit the Diabetes Prevention Program Home Page

TITLE OF STUDY:	The Diabetes Prevention Program-St. Luke's-Roosevelt Hospital Center
PRINCIPAL INVESTIGATOR	Xavier Pi-Sunyer, M.D., M.P.H.
CO-INVESTIGATOR:	Sandra Foo, M.D.
CONTACT PERSON:	Gretchen Van Wye, M.A., Recruitment Coordinator
EMAIL:	70752.35@compuserve.com
PHONE:	(212) 523-8928; (212) 523-8989 main number
FAX:	(212) 523-8428
MAIL:	432 W. 58th Street, Suite 625 New York, NY 10019

INCLUSION

Men and women from all ethnic groups
Ages 25 years and older
Impaired glucose tolerance based on a single 75gm OGTT
- Fasting plasma glucose 95-125 mg/dL AND
- 2-hr plasma glucose 140-199 mg/dL
Body-mass Index:
- 24 kg/m2 and above
- 22 kg/m2 and above for Asian Americans

EXCLUSION

Major health and psychiatric disorders
Inability to walk
Planned pregnancy within the next 5 years.
Medication use:
- Thiazide diuretic and Beta Blocker Antihypertensives
- Niacin used as a Lipid lowering agent
- Antipsychotic agents (Haldol, Loxitane, Mellaril, etc.)
- SSRIs (dose-dependent)
- Bronchodilators (Aminophylline & Inhaled beta- agonists, if used daily)
- Phenytoin
- Amphetamines
- Prescription weight-loss drugs

HONORARIA: $150/year for transportation

PURPOSE: The Diabetes Prevention Program (DPP) is investigating the best ways --both pharmacologic and lifestyle -- to prevent or delay the onset of type 2 diabetes in people at high risk. People who are overweight (even slightly), over 25, related to someone who has diabetes, or who had diabetes while pregnant are at risk for adult- onset diabetes. Those who are African, Asian, Native and Latino Americans are at an even higher risk. The DPP is the largest diabetes prevention study ever undertaken in the United States. For more information on how to participate in this six-year landmark study at no cost to you, please call 212-523-8989 or email 70752.35@compuserve.com

TREATMENT PROGRAMS
OBESITY RESEARCH CENTER HOME PAGE